5-benzo[1,3]dioxol-5-ylmethyl-2H-tetrazole | 32688-20-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 5-benzo[1,3]dioxol-5-ylmethyl-2H-tetrazole
• 英文别名: 5-Piperonyltetrazol；5-Piperonyl tetrazole；5-(1,3-benzodioxol-5-ylmethyl)-2H-tetrazole
• CAS: 32688-20-3
• 化学式: C₉H₈N₄O₂
• 分子量: 204.188
• InChiKey: NQIKAUPICCZAIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  72.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1,3-苯并二氧杂环戊烯-5-乙腈 在 sodium azide 、 氯化铵 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 5-benzo[1,3]dioxol-5-ylmethyl-2H-tetrazole
  参考文献：
  名称：

  McCaustland,D.J. et al., Journal of Heterocyclic Chemistry, 1971, vol. 8, p. 89 - 97

  摘要：

  DOI：

文献信息

• Stable reagent for formazan-based assay
  申请人：Kirkegaard & Perry Laboratories, Inc.

  公开号：EP0971037A2

  公开（公告）日：2000-01-12

  This invention relates to a stable, all-in-one aqueous reagent comprising 5-methyl-phenazinium methyl sulfate (phenazine methosulfate (PMS)), nitric acid and a metal salt wherein the metal is selected from the group consisting of vanadium, manganese, cobalt, and mixtures thereof, useful in assays which use alkaline phosphatase as a reporter enzyme and a reduction of a tetrazolium salt to a formazan as a detection/signaling system for detecting or quantifying a target substance in a sample.

  本发明涉及一种稳定的多合一水基试剂，由 5-甲基酚嗪甲基硫酸盐（酚嗪甲硫酸盐（PMS））、硝酸和金属盐组成，其中金属选自由钒、锰、钴和它们的混合物组成的组、钴及其混合物组成的组中，适用于使用碱性磷酸酶作为报告酶，并将四唑盐还原为甲臢作为检测/信号系统来检测或定量样品中的目标物质的检测方法。
• Dental composition
  申请人：3M Innovative Properties Company

  公开号：EP2052712A1

  公开（公告）日：2009-04-29

  The present invention relates to a bacteria detecting dental composition comprising a solution of at least one electron acceptor and at least one electron donor wherein the electron acceptor and the electron donor are selected that in the solution itself the electron donor can not transmit reduction equivalents to the electron acceptor and wherein the dental composition is substantially free of compounds that enable or facilitate the electron transmission between the electron acceptor and the electron donor. The present invention further relates to the use of a composition comprising a solution of at least one electron acceptor and at least one electron donor wherein the electron acceptor and the electron donor are selected that in the solution itself the electron donor can not transmit reduction equivalents to the electron acceptor and wherein the composition is substantially free of compounds that enable or facilitate the electron transmission between the electron acceptor and the electron donor for site-directed intraoral detection of bacteria.

  本发明涉及一种细菌检测牙科组合物，该组合物包含至少一种电子受体和至少一种电子供体的溶液，其中电子受体和电子供体被选择为在溶液本身中电子供体不能向电子受体传递还原当量，并且该牙科组合物基本上不含能够或促进电子受体和电子供体之间电子传递的化合物。 本发明进一步涉及一种由至少一种电子受体和至少一种电子供体的溶液组成的组合物的用途，其中电子受体和电子供体被选择为在溶液本身中电子供体不能向电子受体传递还原当量，并且该组合物基本上不含能够或促进电子受体和电子供体之间电子传递的化合物，用于口腔内定点细菌检测。
• METHOD FOR DETERMINING THE PRODUCTION OF REACTIVE OXYGEN SPECIES IN A CELLULAR POPULATION
  申请人：Universitat Autònoma De Barcelona

  公开号：EP2637019A1

  公开（公告）日：2013-09-11

  The invention relates to a method for determining the production of reactive oxygen species in a cellular population. The invention also relates to a method for determining the need for an antioxidant treatment of a male subject, and to a method for identifying a substance that can reduce the reactive oxygen species in a cellular population.

  本发明涉及一种确定细胞群中活性氧产生情况的方法。本发明还涉及一种确定男性受试者是否需要抗氧化剂治疗的方法，以及一种确定能够减少细胞群中活性氧的物质的方法。
• Methods and compositions for the visualization of cellular organelles using tetrazolium salts
  申请人：——

  公开号：US20020086345A1

  公开（公告）日：2002-07-04

  The invention provides a biochemical method for visualizing cellular organelles (such as centrosome) and/or cytoskeletons (such as microtubules) through the use of crystallizing agents (such as tetrazolium salts), a kit containing crystallizing agents adapted for such uses, and to methods particularly for detecting neoplastic cells in a tissue sample, suspension, or a fluid sample by examining the cells for abnormalities of cellular organelles (such as centrosome) and/or cytoskeletons (such as microtubules) in the number and shapes.

  本发明提供了一种通过使用结晶剂（如四唑盐）观察细胞器（如中心体）和/或细胞骨架（如微管）的生化方法，一种含有适用于这种用途的结晶剂的试剂盒、以及通过检查细胞中细胞器（如中心体）和/或细胞骨架（如微管）的数量和形状是否异常来检测组织样品、悬浮液或液体样品中肿瘤细胞的方法。
• Method and composition for treating cancer using cellular organelle crystallizing agents
  申请人：——

  公开号：US20020143042A1

  公开（公告）日：2002-10-03

  This invention provides a method for treating cancer in mammals through cellular-organelle-crystallization-induced-death (herein defined as “Cocid”), a method for treating cancer using cellular organelle and/or cytoskeleton crystallizing agents (e.g. tetrazolium salts and their derivatives), pharmaceutical compositions containing a therapeutically effective amount of organelle and/or cytoskeleton crystallizing agents, and compositions containing organelle and/or cytoskeleton crystallizing agents in combination With a pharmaceutically acceptable carrier, diluent or excipient. The crystallizing agents with or without a pharmaceutically acceptable carrier, diluent or excipient, are used in combination with surgery and/or non-surgical anti-tumor treatments.

  本发明提供了一种通过细胞器-结晶-诱导死亡（此处定义为 "Cocid"）治疗哺乳动物癌症的方法，一种使用细胞器和/或细胞骨架结晶剂（如四唑盐及其衍生物）治疗癌症的方法，一种含有治疗有效量的细胞器和/或细胞骨架结晶剂的药物组合物，以及含有细胞器和/或细胞骨架结晶剂的组合物。四唑盐及其衍生物）、含有治疗有效量的细胞器和/或细胞骨架结晶剂的药物组合物，以及含有细胞器和/或细胞骨架结晶剂与药学上可接受的载体、稀释剂或赋形剂的组合物。结晶剂与或不与药学上可接受的载体、稀释剂或赋形剂结合，可用于手术和/或非手术抗肿瘤治疗。